Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma (SRCC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01824966|
Recruitment Status : Completed
First Posted : April 5, 2013
Last Update Posted : April 5, 2013
|Condition or disease|
|Adenocarcinoma Esophageal Cancer|
Adenocarcinoma (ADC) of the esophagus and gastroesophageal junction (GEJ) is an aggressive neoplasm and has a poor prognosis. Surgical based treatment has been the treatment of choice for localized esophageal adenocarcinoma.
Signet-ring cell carcinoma is a unique histologic subtype of adenocarcinoma characterized by abundant intracellular mucin accumulation and a compressed nucleus displaced toward one extremity of the cell (the so-called signet-ring cell (SRC)). According to the World Health Organisation (WHO), a true signet-ring cell carcinoma (SRCca) is defined as an adenocarcinoma in which the predominant component (more than 50% of the tumor) consists of isolated or small groups of SRC in the stroma. If the tumor contains less than 50% of those cells, it is generally considered as an adenocarcinoma (ADC).
|Study Type :||Observational|
|Actual Enrollment :||82 participants|
|Official Title:||Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||December 2012|
|Actual Study Completion Date :||December 2012|
Adenocarcinoma containing < 50% of signet ring cells
Adenocarcinoma containing > 50% of signet ring cells
- Cancer specific 5 year survival in SRCC [ Time Frame: from surgery ]Cancer specific 5 year survival classified into two groups according to WHO criteria (>50% SRC or <50% SRC)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01824966
|University Hospital Leuven; Dept. of Thoracic Surgery|
|Leuven, Belgium, 3000|
|Principal Investigator:||Philippe Nafteux, MD||University Hospital Leuven; Dept. of Thoracic Surgery|